Skip to main content

Advertisement

Table 4 Logistic regression analyses of risk factors for failure to achieve therapeutic target within 6 months

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

  OR 95% CI p valuea
Univariate analyses
 Female 1.235 (0.367–4.155) 0.734
 Age 1.012 (0.979–1.045) 0.488
 Disease duration 1.000 (0.994–1.007) 0.969
 CHB status 3.077 (1.349–7.017) 0.008
 TJC28 1.059 0.986–1.137 0.115
 SJC28 1.035 0.951–1.127 0.421
 Pain VAS 1.096 0.897–1.338 0.369
 PtGA 1.192 0.977–1.455 0.083
 PrGA 1.142 0.920–1.418 0.230
 HAQ 1.318 0.880–1.975 0.180
 CRP 1.004 (0.988–1.020) 0.616
 ESR 1.000 (0.987–1.021) 0.949
 RF positivity 1.637 (0.557–4.811) 0.371
 ACPA positivity 0.452 (0.195–1.043) 0.063
 DAS28-CRP 1.394 (0.936–2.077) 0.102
 MMP-3 1.000 (0.999–1.002) 0.751
 mTSS 1.010 (0.995–1.024) 0.195
 Treatment-naïveb 0.300 (0.102–0.881) 0.029
 GCs 1.178 (0.465–2.989) 0.729
 MTX 0.266 (0.099–0.716) 0.009
 LEF 0.468 (0.206–1.060) 0.069
 SSZ 1.350 (0.401–4.543) 0.628
 HCQ 2.064 (0.893–4.768) 0.090
 CysA 2.850 (0.847–9.591) 0.091
 Iguratimod 2.032 (0.604–6.837) 0.252
 Biologic agents 0.555 (0.189–1.631) 0.285
 MTX combined with SSZ and HCQ 1.175 (0.275–5.009) 0.828
 MTX combined with LEF 0.365 (0.155–0.861) 0.021
 Six-month cumulative dose of GCsc 1.000 (1.000–1.001) 0.340
 Six-month cumulative dose of MTX 0.997 (0.993–1.000) 0.049
 Six-month cumulative dose of LEFd 1.000 (0.999–1.000) 0.113
 Six-month cumulative dose of SSZ 1.000 (0.995–1.005) 0.890
 Six-month cumulative dose of HCQ 1.008 (0.994–1.022) 0.245
 Six-month cumulative dose of CysAe 1.000 (1.000–1.000) 0.023
 Six-month cumulative dose of iguratimodf 1.000 (1.000–1.000) 0.259
 Six-month cumulative dose of tocilizumabg 1.000 (0.999–1.000) 0.337
 Six-month cumulative dose of Yi Sai Pu 1.001 (0.999–1.004) 0.322
 Six-month cumulative dose of infliximab 0.997 (0.986–1.009) 0.659
Bivariate models
 CHB status adjusted for treatment-naïve status 2.844 (1.245–6.498) 0.013
 CHB status adjusted for MTX 2.722 (1.177–6.298) 0.019
 CHB status adjusted for the regimen of MTX combined with LEF 3.077 (1.349–7.017) 0.008
 CHB status adjusted for 6-month cumulative dose of MTX 3.077 (1.349–7.017) 0.008
 CHB status adjusted for 6-month cumulative dose of CysA 3.077 (1.349–7.017) 0.008
Multivariate models
 CHB status adjusted for treatment-naïve status, MTX therapy, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA 2.617 (1.140–6.007) 0.023
 CHB status adjusted for treatment-naïve status, 6-month cumulative dose of MTX, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA 2.844 (1.245–6.498) 0.013
  1. ACPA anti-cyclic citrullinated peptide antibody, CHB chronic hepatitis B (HBV) infection, CI confidence interval, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, ESR erythrocyte sedimentation rate, GCs glucocorticosteroids, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, LEF leflunomide, mTSS modified total Sharp score, MTX methotrexate, OR odds ratio, Pain VAS pain visual analogue scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RF rheumatoid factor, SJC28 28-joint swollen joint count, SSZ sulfasalazine, TJC28 28-joint tender joint count
  2. aCalculated using conditional logistic regression analysis: univariate logistic regression analysis was performed on variables, including baseline characteristics, CHB status, and rheumatoid arthritis medications after enrollment (including categories of medications, 6-month cumulative doses of medications, and different regimens of combined therapies); bivariate analysis was performed by adjusting for the significant univariate factors individually; due to the multicollinearity between MTX therapy and 6-month cumulative dose of MTX, two multivariate models (MTX therapy model and 6-month cumulative dose of MTX model) were set up respectively by adjusting for all significant univariate factors: bold p values are significant
  3. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment
  4. cSix-month cumulative dose of GCs: OR 1.000220, 95% CI 0.999768–1.000671; p = 0.340
  5. dSix-month cumulative dose of LEF: OR 0.999738, 95% CI 0.999414–1.000062; p = 0.113
  6. eSix-month cumulative dose of CysA: OR 1.000077, 95% CI 1.000011–1.000143; p = 0.023
  7. fSix-month cumulative dose of iguratimod: OR 1.000080, 95% CI 0.999941–1.000218; p = 0.259
  8. gSix-month cumulative dose of tocilizumab: OR 0.999656, 95% CI 0.998954–1.000358; p = 0.337